Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.

被引：0
|
作者：
Carulla, Yannick
Neidhardt, Eve-Marie
Karabajakian, Andy
Gauduchon, Thibault
Guevara, Hemerson
Roux, Pierre Eric
Zrounba, Philippe
Podeur, Fabien
Poupart, Marc
Excoffier, Aude
Fayette, Jerome
机构：
[1] Ctr Leon Berard, Lyon, France
[2] 28 Promenade Lea & Napoleon Bullukian, Lyon, France
[3] Owkin France, Paris, France
[4] Ctr Leon Berad, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18027
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Garralda, E.
    Villacampa Javierre, G.
    Feliu, B.
    Martinez, S.
    Gutierrez, R.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - 59
  • [2] The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
    Scheff, Nicole N.
    Nilsen, Marci Lee
    Li, Jinhong
    Harris, Alexandria L.
    Swartz, Andrew
    Hsieh, Ronan Wenhan
    Anderson, Jennifer Lynn
    Ferris, Robert L.
    Menk, Ashley
    Delgoffe, Greg M.
    Zandberg, Dan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Mirallas, O.
    Marmolejo Castaneda, D. H.
    Illescas, D. G.
    Gomez-Puerto, D.
    Berche, R.
    Calvo, A. H.
    Vieito Villar, M.
    Lorini, L.
    Navarro, V.
    Assaf Pastrana, J. D.
    Saavedra, O.
    Alonso, G.
    Aguilar Izquierdo, S.
    Bescos, C.
    Lorente, J.
    Giralt, J.
    Dienstmann, R.
    Garralda, E.
    Felip, E.
    Brana, I.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S856 - S857
  • [4] Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Chow, Laura Quan Man
    Mehra, Ranee
    Haddad, Robert I.
    Mahipal, Amit
    Weiss, Jared
    Berger, Raanan
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Le, Dung T.
    Muro, Kei
    Geva, Ravit
    Chung, Hyun Cheol
    Lin, Chia-Chi
    Ayers, Mark
    Aurora-Garg, Deepti
    Lunceford, Jared K.
    Cheng, Jonathan D.
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Geiger, J. L.
    Egloff, A. M.
    Ohr, J.
    Stabile, L.
    Gooding, W.
    Flaherty, J.
    Gibson, M.
    Grandis, J.
    Bauman, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 930 - 930
  • [7] Characteristics of very long responder to maintenance cetuximab after a platinum-cetuximab based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinomas (RM HNSCC)
    Tardy, Magalie Pascale
    Lescure, Celine
    Doyen, Jerome
    Daste, Amaury
    Lange, Martin
    Saint-Ghislain, Mathilde
    Lefebvre, Gautier
    Sarradin, Victor
    Bozec, Alexandre
    Saada-Bouzid, Esma
    Peyrade, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Ji, D.
    Sang, Y.
    Liu, X.
    Guo, Y.
    Yang, Y.
    Chen, G.
    Dong, S.
    Wang, Y.
    He, X.
    Ying, H.
    Lu, X.
    Wang, Y.
    Hu, C.
    Ji, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S626 - S626
  • [9] Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Chung, Christine H.
    Saba, Nabil F.
    Steuer, Conor Ernst
    Li, Jiannong
    Bhateja, Priyanka
    Johnson, Matthew
    Masannat, Jude
    Poole, Maria
    Hoening, Dirk
    Song, Feifei
    Hernandez-Prera, Juan C.
    Molina, Helen
    Wenig, Bruce
    Farinhas, Joaquim
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Schell, Michael J.
    Bonomi, Marcelo Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Villacampa Javierre, G.
    Garralda, E.
    Gutierrez, R.
    Feliu, B.
    Martinez, S.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
12345